ANTIBODIES
The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Europäisches Patentamt - (2021) vom: 29. Dez. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
GROSVELD FRANKLIN GERARDUS [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 |
---|
Patentnummer: |
EP3927432 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA014697017 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA014697017 | ||
003 | DE-627 | ||
005 | 20240301100627.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230215s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA014697017 | ||
035 | |a (EPA)EP3927432 | ||
035 | |a (EPA)69723908 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a GROSVELD FRANKLIN GERARDUS |e verfasserin |4 aut | |
245 | 1 | 0 | |a ANTIBODIES |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 | ||
520 | |a The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection. | ||
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a VAN HAPEREN MARINUS JOHANNES |4 aut | |
700 | 0 | |a DRABEK DUBRAVKA |4 aut | |
700 | 0 | |a BOSCH BEREND JAN |4 aut | |
700 | 0 | |a WIDJAJA IVY |4 aut | |
700 | 0 | |a WANG CHUNYAN |4 aut | |
700 | 0 | |a VAN DIEREN BRENDA |4 aut | |
700 | 0 | |a LI WENTAO |4 aut | |
700 | 0 | |a VAN KUPPEVELD FRANK J M |4 aut | |
700 | 0 | |a HAAGMANS BART L |4 aut | |
700 | 0 | |a OKBA NISREEN M A |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 29. Dez. |
773 | 1 | 8 | |g year:2021 |g day:29 |g month:12 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/69723908/publication/EP3927432A1?q=EP3927432 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2021 |b 29 |c 12 |